BMS-986408 + nivolumab + platinum-doublet chemotherapy

**BMS-986408 + nivolumab + platinum-doublet chemotherapy** is a combination therapy under investigation for advanced solid tumors, including non-small cell lung cancer. BMS-986408 is a first-in-class dual inhibitor of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), which act as negative regulators of T-cell signaling. By inhibiting these kinases, BMS-986408 enhances T-cell-mediated anti-tumor activity. Nivolumab is a monoclonal antibody that inhibits programmed death-1 (PD-1), relieving immune suppression and enabling T-cell attack on cancer cells. Platinum-doublet chemotherapy typically combines a platinum-based agent (e.g., cisplatin or carboplatin) with a second cytotoxic chemotherapeutic (such as gemcitabine, pemetrexed, or paclitaxel) and remains a standard of care for various cancers. This regimen is being tested to maximize anti-tumor immune response by integrating direct cytotoxicity with immune checkpoint inhibition and DGKα/ζ blockade[3][4][5][7].

Other names

platinum-doublet chemotherapy